In another phase I study combining paclitaxel and palbociclib alternating sequential palbociclib and paclitaxel in patients with Rb + advanced breast cancer was safe and feasible without additional toxicity with clinical benefit rate of 55% at the recommended phase 2 dose level(16). This evidence concerns the gene RB1 and breast carcinoma.